Recipharm AB (RECI B):企業の財務・戦略的SWOT分析

◆英語タイトル:Recipharm AB (RECI B) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1634
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,125見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,375見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Recipharm AB (RECI B) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Recipharm AB (Recipharm) is a contract development and manufacturing organization (CDMO) that offers manufacturing, and development and technology services. The company’s manufacturing services include contract manufacturing of pharmaceuticals such as semi-solids, and oral liquids, solid dose, sterile products, besides clinical trial materials including APIs and other drugs. Recipharm’s development and technology services supports customers from initial product concept to the approved commercial pharmaceutical drug. It includes services such as raw material supply, formulation, validated analytical methods, among others. The company operates in the UK, Germany, Spain, Italy, Sweden, France, Portugal, India, Israel and the US. Recipharm is headquartered in Stockholm, Sweden.

Recipharm AB Key Recent Developments

Mar 06,2020 Recipharm completes delisting of Consort Medical
Mar 06,2020 Recipharm notes an increased demand for Chloroquine Phosphate

Feb 20,2020 Recipharm publishes report for the fourth quarter and full year 2019
Feb 07,2020 Recipharm announces that Consort Medical applies for delisting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Recipharm AB – Key Facts
Recipharm AB – Key Employees
Recipharm AB – Key Employee Biographies
Recipharm AB – Major Products and Services
Recipharm AB – History
Recipharm AB – Company Statement
Recipharm AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Recipharm AB – Business Description
Business Segment: D&T
Overview
Performance
Business Segment: MFG-SI
Overview
Performance
Business Segment: MFG-SO
Overview
Performance
Geographical Segment: France
Performance
Geographical Segment: Germany
Performance
Geographical Segment: India
Performance
Geographical Segment: Italy
Performance
Geographical Segment: Other
Performance
Geographical Segment: Portugal
Performance
Geographical Segment: Spain
Performance
Geographical Segment: Sweden
Performance
Geographical Segment: UK
Performance
Recipharm AB – Corporate Strategy
Recipharm AB – SWOT Analysis
SWOT Analysis – Overview
Recipharm AB – Strengths
Recipharm AB – Weaknesses
Recipharm AB – Opportunities
Recipharm AB – Threats
Recipharm AB – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Recipharm AB, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 06, 2020: Recipharm completes delisting of Consort Medical
Mar 06, 2020: Recipharm notes an increased demand for Chloroquine Phosphate
Feb 20, 2020: Recipharm publishes report for the fourth quarter and full year 2019
Feb 07, 2020: Recipharm announces that Consort Medical applies for delisting
Feb 05, 2020: Consort Medical becomes part of the Recipharm Group
Dec 09, 2019: Recipharm invests in its US inhalation development service
Nov 18, 2019: Recipharm to communicate new financial targets on Capital Markets Day
Nov 14, 2019: Recipharm joins the AMR Industry Alliance
Nov 07, 2019: Recipharm publishes its interim report January – September 2019
Nov 06, 2019: Recipharm expands Indian injectable dosage form capabilities through new partnership
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Recipharm AB, Key Facts
Recipharm AB, Key Employees
Recipharm AB, Key Employee Biographies
Recipharm AB, Major Products and Services
Recipharm AB, History
Recipharm AB, Other Locations
Recipharm AB, Subsidiaries
Recipharm AB, Key Competitors
Recipharm AB, Ratios based on current share price
Recipharm AB, Annual Ratios
Recipharm AB, Annual Ratios (Cont...1)
Recipharm AB, Annual Ratios (Cont...2)
Recipharm AB, Interim Ratios
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Recipharm AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Recipharm AB, Performance Chart (2015 - 2019)
Recipharm AB, Ratio Charts
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Recipharm AB, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Recipharm AB (RECI B):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SNGN Romgaz SA (SNG):石油・ガス:M&Aディール及び事業提携情報
    Summary SNGN Romgaz SA (Romgaz), formerly Societatea Nationala de Gaze Naturale Romgaz SA, is an oil and gas company which explores, produces and supplies natural gas. The company's activities include exploration of petroleum onshore and offshore, natural gas production, electric power production, t …
  • Exact Holding N.V.:企業の戦略的SWOT分析
    Exact Holding N.V. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • AB Science SA (AB):製薬・医療:M&Aディール及び事業提携情報
    Summary AB Science SA (ABS) is a pharmaceutical company focused on discovery, development, and commercialization of protein kinase inhibitors. The company's lead compound Masitinib, is a orally administered tyrosine kinase inhibitor targeting mast cells and selected kinases, including c-Kit, PDGFR, …
  • Mosenergo (MSNG):電力:M&Aディール及び事業提携情報
    Summary Mosenergo, a subsidiary of Gazprom Energoholding LLC, is a power utility. It generates electricity and thermal energy using natural gas, coal, fuel oil, and diesel sources. The company owns and operates power plants: TPP-20, SDPP-3, TPP-9, SPP-1, TPP-21, TPP-8, TPP-11, TPP-16, TPP-12, TPP-17 …
  • PeriGen Inc-医療機器分野:企業M&A・提携分析
    Summary PeriGen Inc (PeriGen), formerly E&C Medical Intelligence Inc is a healthcare technology company that offers advanced obstetric decision-support systems. The company offers fetal monitoring systems which include tracings, patterns, curve and shoulder screen systems. Its decision-support softw …
  • Cinkarna Celje d.d. Celje (CICG):企業の財務・戦略的SWOT分析
    Cinkarna Celje d.d. Celje (CICG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Clinical Innovations LLC-医療機器分野:企業M&A・提携分析
    Summary Clinical Innovations LLC (Clinical Innovations), a subsidiary of Pritzker Group Company is a medical device company that offers healthcare products for women and infants. The company offers products such as safety heelsticks, traxi panniculus retractor, ROM plus membrane testing, tamponade s …
  • Vossloh AG:企業の戦略・SWOT・財務情報
    Vossloh AG - Strategy, SWOT and Corporate Finance Report Summary Vossloh AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Manchester United Plc:企業の戦略・SWOT・財務分析
    Manchester United Plc - Strategy, SWOT and Corporate Finance Report Summary Manchester United Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • MacroGenics Inc (MGNX):製薬・医療:M&Aディール及び事業提携情報
    Summary MacroGenics Inc (MacroGenics) is a clinical-stage biopharmaceutical company which focuses on the discovery, development and delivery of novel antibody-based therapeutics for the treatment of cancer, infectious diseases and autoimmune disorders. Its pipeline includes product candidates for th …
  • Coloplast AS (COLO B):医療機器:M&Aディール及び事業提携情報
    Summary Coloplast A/S (Coloplast) is a medical device company that offers products and services for ostomy care, urology care, continence care, and skin and wound care. Its major products include ostomy bags; urisheaths; urine bags; catheters; anal irrigation systems; vaginal sling products; advance …
  • Bicycle Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Bicycle Therapeutics Ltd (Bicycle Therapeutics) is a biotechnology company that develops bicyclic peptides Medicines for the treatment of cancers and other debilitating diseases. The company's proprietary bicyclic peptide technology enables systematic cyclisation of peptides and helps to ide …
  • Spectris plc:企業の戦略・SWOT・財務情報
    Spectris plc - Strategy, SWOT and Corporate Finance Report Summary Spectris plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Studsvik AB (SVIK):企業の財務・戦略的SWOT分析
    Studsvik AB (SVIK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Deutsche Borse AG:企業の戦略・SWOT・財務情報
    Deutsche Borse AG - Strategy, SWOT and Corporate Finance Report Summary Deutsche Borse AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Absorption Systems LP-製薬・医療分野:企業M&A・提携分析
    Summary Absorption Systems LP (Absorption Systems) is a pre-clinical contract research organization that develops and implements research tools. The organization carries out preclinical testing of drugs, biologics, and medical devices. It develops and implements research tools to predict human outco …
  • Mitsui Oil Exploration Co Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Mitsui Oil Exploration Co., Ltd. (MOECO), a subsidiary of Mitsui & Co., Ltd, is an upstream oil and gas company. The company explores for, develops and produces oil, natural gas and condensate from its assets. It is also involved in a geothermal energy project. The company also holds investm …
  • Targa Resources Corp.:企業の戦略・SWOT・財務情報
    Targa Resources Corp. - Strategy, SWOT and Corporate Finance Report Summary Targa Resources Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Great Eastern Holdings Limited (G07):企業の財務・戦略的SWOT分析
    Great Eastern Holdings Limited (G07) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Ampio Pharmaceuticals Inc (AMPE):企業の財務・戦略的SWOT分析
    Summary Ampio Pharmaceuticals Inc (Ampio), formerly Chay Enterprises Inc is a biopharmaceutical company that discovers and develops novel therapeutic candidates for inflammatory conditions. The company develops compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆